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Abstract
Background: The process of cellular differentiation is governed by complex dynamical biomolecular
networks consisting of a multitude of genes and their products acting in concert to determine a particular
cell fate. Thus, a systems level view is necessary for understanding how a cell coordinates this process and
for developing effective therapeutic strategies to treat diseases, such as cancer, in which differentiation
plays a significant role. Theoretical considerations and recent experimental evidence support the view that
cell fates are high dimensional attractor states of the underlying molecular networks. The temporal
behavior of the network states progressing toward different cell fate attractors has the potential to
elucidate the underlying molecular mechanisms governing differentiation.
Results: Using the HL60 multipotent promyelocytic leukemia cell line, we performed experiments that
ultimately led to two different cell fate attractors by two treatments of varying dosage and duration of the
differentiation agent all-trans-retinoic acid (ATRA). The dosage and duration combinations of the two
treatments were chosen by means of flow cytometric measurements of CD11b, a well-known early
differentiation marker, such that they generated two intermediate populations that were poised at the
apparently same stage of differentiation. However, the population of one treatment proceeded toward the
terminally differentiated neutrophil attractor while that of the other treatment reverted back toward the
undifferentiated promyelocytic attractor. We monitored the gene expression changes in the two
populations after their respective treatments over a period of five days and identified a set of genes that
diverged in their expression, a subset of which promotes neutrophil differentiation while the other
represses cell cycle progression. By employing promoter based transcription factor binding site analysis,
we found enrichment in the set of divergent genes, of transcription factors functionally linked to tumor
progression, cell cycle, and development.
Conclusion: Since many of the transcription factors identified by this approach are also known to be
implicated in hematopoietic differentiation and leukemia, this study points to the utility of incorporating a
dynamical systems level view into a computational analysis framework for elucidating transcriptional
mechanisms regulating differentiation.
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Background
The process of cellular differentiation is central to our
understanding of the nature of multicellular living sys-
tems, their stability in a changing environment, and how
such systems fail in diseases, such as cancer [1,2]. This
developmental process of individual cells in a multicellu-
lar organism committing to their specialized phenotypic
characteristics is temporally coordinated by a complex
dynamical system comprised of large numbers of interact-
ing genes and their products [3-5]. Not surprisingly,
dynamical systems theory has been used to study cell dif-
ferentiation [6-8].
Despite its tremendous importance, there is very little
accumulated knowledge of the process of differentiation
from a systems perspective and of the role of molecular
programs involved in this process. Even for an agent that
causes differentiation to a common recognizable state, we
do not know whether the cells, as manifestations of the
underlying dynamic bio-molecular systems, always fol-
low common or different molecular paths (or system state
trajectories). In the latter case, we also do not know which
of those paths is the most stable and least reversible.
Since a cell's phenotype and behavior are largely deter-
mined by the activities of the genes and proteins constitut-
ing a genetic network, it follows that the rules of
interactions between these elements translate directly into
rules of cellular behavior. That is, the enormous state
space of a genetic network (i.e., the space of all possible
configurations activities of the constituent elements)
becomes reduced into a relatively small number of trajec-
tories and steady states (attractors) of the dynamical sys-
tem. Kauffman postulated that these attractor states in
model networks correspond to the cell types in multicel-
lular organisms [9,10], and the process of differentiation
corresponds to a trajectory (in the state space) leading into
one of the attractors. The cellular fate is thus determined
by the attractor in which the genetic network eventually
ends up; this can, to a large extent, be controlled by appro-
priate external stimuli that place the system into different
initial states. It is important to note that many trajectories
ensuing from such different initial states can flow to a
common attractor and thus constitute its basin of attrac-
tion.
Consider that small molecule chemicals, such as dimethyl
sulfoxide (DMSO) and a host of others can induce cell dif-
ferentiation in a variety of cell systems along with con-
comitant cellular properties [11-15]. This rather amazing
fact implies the pre-existence of cellular fates that need
only be selected by means of external stimuli rather than
created by specific molecular events. This 'selection' of cell
fates occurs by means of the inherent nature of the
dynamical system to flow to an attractor when placed in
some initial transient state and thus, differentiation is a
process of selecting a particular attractor in a genetic regu-
latory network. This view has been supported experimen-
tally by Huang et al. using genome-wide mRNA
expression profiling [16] as well as by means of analyzing
cell fates in response to generalized physical stimuli, such
as cell distortion [17]. For a more extended discussion on
this topic, see [10].
The homeostatic stability of a differentiated cell is a con-
sequence of the underlying stability of the attractor –
'nearby' states, which may occur as a consequence of nat-
ural environmental variation, simply flow back to the
attractor. It is known that normal cells have a balanced
state of proliferation and differentiation, resulting in
homeostatic stability [18,19]. A block of normal differen-
tiation and abnormal reversal of differentiation (some-
times called de-differentiation) [20] are believed to be
some of the hallmarks of cancer [21]. Accordingly, thera-
peutic strategies have been designed to facilitate cancer
cells to reenter the differentiation program, often termed
differentiation therapy [22,23].
The success of such therapeutic strategies depends on our
ability to systematically determine appropriate molecular
'lever points', the perturbations of which place the biomo-
lecular system into states that are poised to differentiate.
Indeed, such a strategy corresponds to placing the system
in a state by means of a stimulus, such as a therapeutic
agent, and allowing the system to naturally flow toward
an attractor that corresponds to the desired cellular end-
point [24-26]. To identify such targets for intervention, it
is necessary to characterize the underlying molecular
mechanisms, such as transcriptional regulatory networks,
governing the process of differentiation. Systems biology
approaches, which are predicated on global measure-
ments and data integration, are now beginning to reveal
transcriptional machinery underlying complex biological
processes [27-30]. The rationale behind our study was to
explore whether the aforementioned systems-level view of
cell fates as attractors and differentiation as a route toward
an attractor, when coupled with computational systems
biology approaches, is informative for elucidating the
transcriptional regulatory mechanisms governing differ-
entiation.
To this end, we have selected a well-established differenti-
ation model, human promyelocytic leukemia cells
(HL60) originally isolated by Dr. Steven Collins from a
37-year-old female acute promyelocytic leukemia (APL)
patient [31]. The HL60 is a multi-potent cell line that can
be stimulated to differentiate using a variety of chemical
agents, including DMSO [32], all-trans-retinoic acid
(ATRA) [33], 1,25 -dihydroxyvitamin D3 [34], 12-O-tetra-
decanoylphorbol 13-acetate (TPA) [35], and granulocyteBMC Systems Biology 2009, 3:20 http://www.biomedcentral.com/1752-0509/3/20
Page 3 of 13
(page number not for citation purposes)
macrophage colony-stimulating factor (GM-CSF) [36].
With the addition of ATRA, the HL60 cells differentiate
into neutrophils, while displaying the early differentia-
tion marker, CD11b, which begins to be expressed within
one day of treatment [37]. Although there are others,
CD11b is an early differentiation marker, which allows
one to capture the initial stage of the process. The CD11b+
differentiated HL60 cells can be stained with fluorescent-
labeled anti-CD11b antibody and easily recognized by
commonly used flow-cytometry methods and isolated by
flow-sorting for further culturing and experimentation, as
we have done here. The HL60 system was also used by
Huang  et al. [16] to demonstrate the correspondence
between cell fates and high-dimensional attractor states of
the underlying genetic network.
One could reason as follows. If we could place the HL60
into a state from which the system would dynamically
flow towards the "neutrophil" attractor, as demonstrated
by Huang et al., then the genes that show altered behavior
along the time-course trajectory relative to unstimulated
controls could be hypothesized to be implicated in the
neutrophil differentiation process. This, of course, may be
the case, though the interpretation is confounded by the
possibility that the genes exhibiting altered behavior are
responsive to the particular mechanisms activated by the
stimulus used, such as ATRA. Indeed, Huang et al. also
confronted this conceptual difficulty when they compared
trajectories from ATRA-treated and DMSO-treated HL60
cells, finding that certain genes may behave differently
simply as a result of different stimuli activating different
biological pathways, while many other genes dynamically
converge towards a common attractor, despite the system
flowing from distinct starting states corresponding to
ATRA and DMSO treatments [16]. To identify genes that
are not stimulus dependent, but are involved in the proc-
ess of neutrophil differentiation, one could then use only
one treatment, but in a way that allows one to alter cellu-
lar fate, namely, terminal differentiation into neutrophils
or reversion back to the undifferentiated state.
The HL60 was shown to exhibit such behavior in two sep-
arate studies both demonstrating that this differentiation
process contains at least two steps in which a precommit-
ment stage precedes the decision to differentiate. Yen et al.
observed that with continuous exposure of ATRA at a high
concentration, the HL60 proceeds through differentia-
tion, but upon removal of the stimulus, the HL60 falls
back to the undifferentiated state [38]. By analogy, such a
precommitment stage corresponds to a gradually sloping
plateau between a valley and a mountain such that a ball
sitting on this plateau would roll down into the "undiffer-
entiated" valley in the absence of additional energy neces-
sary to make it over the "terminally differentiated"
mountain. More recently, Chang et al. reported a popula-
tion of "primed," undifferentiated CD11b- cells upon
exposure to a low dose DMSO [39]. Though these cells are
negative with respect to the CD11b marker, thus consid-
ered to be "undifferentiated," upon encountering a sec-
ond dose of DMSO stimulation, they exhibited an
increased rate of differentiation, suggesting that the first
low dose DMSO had placed them in a "primed" interme-
diate differentiated state.
We thus decided to determine two different treatments,
both with ATRA, but with different concentrations and
incubation times such that the two cell populations corre-
sponding to these treatments would be poised at the same
stage of differentiation (precommitment), but so that one
population follows through to the terminally differenti-
ated neutrophil attractor, while the other reverts back by
dynamically flowing towards the undifferentiated state.
The genes that would exhibit different behavior between
these two trajectories would then be potentially impli-
cated in the differentiation process.
To identify two such precommitment states, we used the
percentage of CD11b+ cells at the end of a particular treat-
ment as a measure of the stage of differentiation. We per-
formed 80 ATRA treatments consisting of 8 doses (0.0005
M to 1  M) and 10 durations (4 to 13 days) in triplicate
and measured percentages of CD11b+ cells, relative to an
isotype antibody control, using FACS analysis. Consider
loci in the two-dimensional dose × duration stimulus
space, where all points on a particular locus correspond to
a constant fraction of CD11b+ cells. Thus, two cell popu-
lations on the same locus can be said to be at the same
"stage" of differentiation at least as it pertains to CD11b.
We chose two such populations, one with a higher dose
and a shorter duration and the other with a lower dose
and a longer duration, such that the cells treated with the
higher dose proceeded with differentiation into neu-
trophils while the cells treated with the lower dose
reverted back to the undifferentiated state, despite both
populations exhibiting the same percentage of CD11b+
cells at the end of their respective treatments. The cells
were live-sorted, cultured in fresh media, and profiled
every 24 hours with microarrays for five days in triplicate.
This additional Fluorescence Activated Cell Sorting
(FACS) step mitigates the confounding effects of cellular
heterogeneity due to subpopulations that do not initiate
the differentiation program (i.e. CD11b- cells). In this
manner, the gene expression programs of the two cell
populations, one differentiating and one reverting, could
be analyzed using computational approaches.
We defined a criterion to identify genes whose behavior
over time exhibits a divergence between the two treat-
ments. It is these genes that are hypothesized to be
involved in the differentiation process. We analyzed theBMC Systems Biology 2009, 3:20 http://www.biomedcentral.com/1752-0509/3/20
Page 4 of 13
(page number not for citation purposes)
promoters of these genes and found that they are overrep-
resented with known transcription factors functionally
linked to myeloid differentiation, cell cycle, and develop-
ment. This study points to the utility of incorporating a
systems-level view of global dynamics, as distinguished
from the dynamics or kinetic behavior of the individual
elements of a system, into a computational analysis
framework that can be used for studying transcriptional
regulatory mechanisms governing a complex biological
process such as differentiation.
Results and discussion
Two comparable dosage/duration treatment combinations 
lead to different macroscopic cell fate attractors
Our first goal was to determine two dosage/duration stim-
ulation conditions that yield comparable stages of differ-
entiated HL60 cells, with one condition ultimately
leading to neutrophil differentiation and the other revert-
ing back to the undifferentiated state. In other words, we
sought to identify two perturbations that place the ATRA-
treated cells in two different basins of attraction or initial
states leading to two different attractors – the promyelo-
cyte attractor and the neutrophil attractor. This informa-
tion allows us to culture large quantities of the HL60 cells
under these conditions and isolate mRNA for time course
experiments to examine the set of genes differentially
expressed between these treatments that could explain the
differences in their eventual cell fates.
To achieve this goal, we set up a two-factor dosage and
duration experiment with eight and ten levels respectively,
ranging from 0.0005  M to 1  M with 4 to 13 days of treat-
ment. We used a well-established early marker for neu-
trophil differentiation, CD11b, as our surrogate for
'differentiated' and 'undifferentiated' state [37]. We meas-
ured the CD11b expression for each experimental condi-
tion and calculated the percentage of HL60 cells that are
CD11b+ by comparing to the untreated samples. Under
this construction, the percentage of CD11b+ cells
becomes a proxy for the developmental stage of neu-
trophil differentiation on a population level. The result of
this dosage and duration experiment is summarized and
displayed in a contour plot (Figure 1), showing a general
trend – as the dosage or duration of ATRA treatment
increases, the percentage of CD11b+ cells also increases.
The treatment combinations, 0.5  M/11 Days produced
the highest percentage of CD11b+ cells at 82.7%. As
expected, this result conforms with our general intuition
regarding ATRA treatment, that an increase in the dosage
or the duration of treatments results in an increase in the
percentage of differentiated CD11b+ cells. See Additional
File 1 for the percentages of CD11b expression of the var-
ious treatments.
From the contour plot, we identified two treatments that
both gave rise to 54 percent of CD11b positive cells,
namely, 1  M/5 Days and 0.05  M/7 Days. These two treat-
ment combinations were picked because they produced
similar levels of positive CD11b expression, yet one treat-
ment is of higher dosage with shorter duration, while the
other is of lower dosage with longer duration. We grew the
HL60 cells under those conditions and isolated the
CD11b+ population of these cells by FACS and re-cul-
tured these cells in fresh, ATRA-free RPMI-1640 media.
We collected the re-cultured cells and isolated the mRNA
for whole-genome expression analysis each day for five
days. At the end of this period, we also collected cells from
both treatments for Wright-Giemsa staining, a histologi-
cal method that could be used to determine hematopoi-
etic cell types based on cell morphology. The 0.05  M/7
Days treatment resembles that of the untreated HL60
cells, with clear visible nucleoli and large nuclear to cyto-
plasm ratios, suggesting a reversal of cell fate back to the
undifferentiated HL60 state; whereas the 1  M/5 Days
treatment shows morphology resembling that of differen-
tiated neutrophils, with characteristic decreased nuclear to
cytoplasmic ratio, and convolution and segmentation of
the nuclei, suggesting a completion of cell fate toward the
differentiated neutrophil attractor. Our observation is in
accordance with the notion of a "precommitment" state
previously described [39-41], whereupon the removal of
Contour plot of the percentage of CD11b+ cells after ATRA  treatment Figure 1
Contour plot of the percentage of CD11b+ cells after 
ATRA treatment. The x-axis represents the duration of 
ATRA treatment (Days). The y-axis represents the dosage of 
ATRA treatment ( M). The ovals represent the 1  M/5 Days 
and 0.05  M/7 Days dosage/duration culture conditions uti-
lized for gene expression analysis. An increase in dosage or 
duration leads to an increase in CD11b+ cells.
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the stimulating agent, the HL60 can revert back to the
undifferentiated state. Taken together, we have estab-
lished a system where we identified two perturbations
that place the HL60 cells in different basins of attraction,
leading to different eventual macroscopic cell fates.
A subset of the genes leading to different cell fate 
attractors exhibit a divergent expression pattern
To understand how the macroscopic cell fates that we
observed could have arisen from these two perturbation
conditions, we analyzed the gene expression profiles of
the treated HL60 cells. We reasoned that we had placed
the treated HL60 cells in their perspective basins of attrac-
tion when we re-cultured the sorted CD11b+ cells from
these two treatments in ATRA-free media. Hence, the gene
expression trajectories reflected the natural consequences
of placing the HL60 cells in these specific parts of the
genomic expression space. Therefore, when we looked at
the gene expression profiles of differentially expressed
genes between the two trajectories, the pattern we
observed could potentially explain the observed macro-
scopic cell fate.
Interestingly, while the majority of the differentially
expressed genes (relative to untreated controls) exhibit a
flat and unchanging average gene expression profie under
both (1  M/5 Days) and (0.05  M/7 Days) treatment con-
ditions, there is a small subset of the genes (154, using our
criterion) that exhibit a divergent gene expression profile.
That is, after the high dosage/short duration treatment (1
M/5 Days), their expression levels deviate further and fur-
ther away from their levels under the untreated ATRA con-
dition, whereas their expression levels after the low
dosage/long duration treatment (0.05  M/7 Days) con-
verge toward the gene expression levels of those under
untreated ATRA condition (Figure 2). These divergent
genes can be separated further into two distinct classes,
the up-regulated, and the down-regulated genes. The up-
regulated (respectively, down-regulated) genes are the
ones that have elevated (respectively, repressed) expres-
sion under both high dosage/short duration and low dos-
age/long duration treatments relative to their expression
under the untreated ATRA condition. In both cases, this
display of differential expression behavior reflects the
macroscopic cell fate observed, namely that the HL60 cells
from the high dosage/short duration treatment continue
toward differentiation whereas cells subjected to low dos-
age/long duration treatment revert back toward the undif-
ferentiated state. We hypothesized that these divergent
genes participate in the selection of a particular attractor
from a set of pre-existing ones. See Additional File 2 for a
list of the divergent genes as well as magnitude of diver-
gence.
Divergent genes promote cellular differentiation and 
repress cell cycle progression
After we identified the set of divergent genes and their
unique gene expression patterns, we set out to investigate
their known biological functions, with the goal of eluci-
dating how these genes coordinate the transition of the
HL60 cells from the promyelocyte attractor into the neu-
trophil attractor. In particular, cellular differentiation
processes frequently entail an up-regulation of genes
involved in specialization while simultaneously down-
regulating genes related to proliferation and cell cycle
[18,19].
Indeed, a number of the up-regulated divergent genes are
involved in the activation and specialization of neu-
trophils. At the top of the up-regulated divergence gene
list is ankyrin repeat and SOCS box-containing 2 (ASB2),
which is known to be a retinoic acid-response gene and a
binding target of the promyelocytic leukemia retinoic acid
receptor-alpha (RAR ) oncogenic protein [42]. When
ASB2 is expressed in leukemia cells, it inhibits growth and
furthers myelocytic commitment, precisely as seen in the
HL60 cell differentiation model system. Inherent to the
process of neutrophil activation are genes promoting the
Average mRNA gene expression of the differentially  expressed genes Figure 2
Average mRNA gene expression of the differentially 
expressed genes. The left panel shows the divergent genes. 
The right panel shows the non-divergent genes. The upper 
parts of the figures represent the genes that are up-regulated 
in both 1  M/5 Days and 0.05  M/7 Days treatments relative 
to untreated controls. The lower parts represent the genes 
that are down-regulated in both 1  M/5 Days and 0.05  M/7 
Days treatments relative to untreated controls.
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homing and migration of neutrophils to the sites of
inflammation. Examples of these genes among this list are
orosomucoid 1 (ORM1), interleukin 8 receptor beta
(IL8R ), and vanin2 (VNN2). ORM1 is highly expressed
during acute inflammation and has been suggested as a
signaling molecule that binds to L-selectin on the neu-
trophil cell surface to allow neutrophils to enter secondary
lymphoid tissues via the high endothelial venules [43].
IL8R , also known as CXCR2, is a receptor of interleukin 8
(IL8) and facilitates neutrophil migration to the site of
inflammation [44]. Recently, its ligand was identified to
be the cytokine, macrophage migration inhibitory factor
(MIF) [45]. Finally, expressed mainly on human neu-
trophils [46] and anchored on the cell surface by glycosyl-
phosphatidylinositol (GPI), VNN2 physically associated
with  2 integrin (CD11b), the neutrophil differentiation
marker for our study [47].
Besides neutrophil activation, response to inflammation
is another process in which several of the up-regulated
divergent genes including leukocyte immunoglobulin-
like receptor subfamily B member 3 (LILRB3) and NOD9
(NLR X1) participate. Expressed LILRB3 protein binds to
the MHC class I molecules on antigen-presenting cells to
control inflammatory responses and cytotoxicity by trans-
ducing a negative signal that inhibits immune response
and limits autoreactivity [45]. NOD9 is a member of the
NLR family known to recognize microbial molecules that
activate inflammatory caspases, causing cleavage and acti-
vation of inflammatory cytokines [48]. Collectively, these
up-regulated divergent genes promote requisite activities
of activated neutrophils.
The list of down-regulated divergent genes, on the other
hand, contains many genes necessary for the progression
of cell cycle. We found members of the well-known cyclin
and cell division cycle (CDC) gene families [49] including
cyclin d2 (CCND2), cyclin E1 (CCNE1), cell division
cycle 2 (CDC2), cell division cycle 7 (CDC7), CDC28 pro-
tein kinase regulatory subunit 1B (CKS1B), and cell divi-
sion cycle associated 5 (CDCA5). CCND2 forms a
complex with cyclin dependent kinase 4 (CDK4) [50] and
regulates cell cycle G0/G1 to S transition [51]. Similarly,
CCNE1 is necessary for the progression of G1 to S transi-
tion. It interacts with cyclin dependent kinase 2 (Cdk2) to
phosphorylate the target genes nuclear protein ataxia-tel-
angiectasia locus (NPAT) and nucleophosmin, critical
components of cell proliferation and DNA replication,
respectively [52]. CDC2 encodes a Ser/Thr kinase and is
the catalytic subunit of M-phase promoting factor (MPF),
critical for G1/S and G2/M transitions [53]. CDC7
encodes a kinase that is essential for DNA replication as
well as the transition between G1/S phase [54]. CKS1B
binds to cyclin A for targeted degradation and passage
through the spindle checkpoint [55]. CDCA5, also known
as sororin, controls the separation of sister chromatids
during mitosis by stabilizing centromeric cohesin [56]. In
addition to the cyclin and CDC gene families, other genes
integral to cell cycle progression were also found. TTK pro-
tein kinase (TTK) is a cell cycle-regulated kinase with max-
imal activity during M phase, localizing to kinetochores
[57]. It is required for centrosome duplication and normal
progression of mitosis [58]. Kinesin family member 20A
(KIF20A) accumulates in mitotic cells where it localizes to
the midzone of the spindle during anaphase, and to the
cleavage furrow and midbody during telophase, essential
for cytokinesis to proceed [59]. Interestingly, KIF20A is a
target of polo like kinase 1 (PLK1), a protein that we also
identified as a divergent gene. Together, they are necessary
for proper spindle assembly and function during ana-
phase and telophase of the cell cycle [60]. Jointly, the
down-regulated divergent genes suppress the HL60 cells
from progressing through the cell cycle.
To complement our literature-search approach to under-
standing the functions of these up and down-regulated
divergent genes, we examined them separately in the con-
text of Gene Ontology (GO) [61] enrichment analysis
using GoMiner [62]. The 154 divergent genes include 48
up-regulated and 106 down-regulated divergent genes out
of a total of 30729 unique genes on the Agilent array.
However, at the relative conservative p-value and FDR
level of 0.05 and due to a relatively small number of up-
regulated divergent genes, we are only able to detect statis-
tical significance of enrichment for the down-regulated
divergent genes. The GO enriched results for the down-
regulated divergent genes are listed in Table 1.
Transcription factor binding site enrichment in promoters 
of divergent genes
We suspected that there may be common regulatory
mechanisms that control the expression of both up and
down-regulated divergent genes to select for the neu-
trophil cell fate attractor and to efficiently activate the nec-
essary biological processes. One common mechanism of
controlling gene expression is through the regulatory
actions of transcription factors; therefore, we set out to
search for enriched transcription factor binding sites
(TFBS) in the promoter regions of both the up and down-
regulated divergent genes simultaneously. We used a
background model composed of upstream 2 kb promoter
sequences of all known genes and compared them to the
upstream promoter sequences of the divergent genes by
calculating the log likelihood ratio score to find the puta-
tive binding sites. Table 2 contains the sorted top 15
enriched transcription factor binding sites.
Functionally, these enriched TFBSs can be broken down
into rough categories of tumor progression, cell cycle,
development, or general transcription, which are proc-BMC Systems Biology 2009, 3:20 http://www.biomedcentral.com/1752-0509/3/20
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esses actively engaged by the HL60 neutrophil differentia-
tion model system. Let us consider the striking roles
played by the transcription factors in tumor progression.
We find TFBSs for C/EBP , HLF, TAL1, HOXA4, MEIS1A,
RAR-RXR, and FOXO4, all of which, when disregulated,
have been shown to lead to leukemia. C/EBP  is crucial for
the process of granulopoiesis, and its aberrant expression
in acute myeloid leukemia is well-studied [63-66]. Condi-
tional expression of C/EBP  leads to neutrophil differenti-
ation while dominant-negative expressions of C/EBP  are
found in AML patients [63]. HLF, together with E2A,
forms a chimeric E2A-HLF transcription factor protein
due to a translocation mutation t(17;19)(q21;p13) which
occurs in a subset of acute lymphoblastic leukemias [67-
69]. TAL1 is essential for early stage embryonic hemat-
opoiesis; erythroid differentiation is associated with
increased TAL1 expression, while myeloid differentiation
is associated with decreassed TAL1 expression [70]. A
TAL1 translocation mutation t(1;14)(p32;q11) is
observed in 3% of patients with T cell acute lymphoblastic
leukemia [71]. HOX genes are an important transcription
factor family for hematopoiesis, the different family mem-
Table 1: Enriched GO categories of down-regulated divergent genes.
GO Terms and Description Total Genes Changed Genes -log10(p)F D R
(Biological Process)
GO:0007049 Cell cycle 597 14 5.7044 0
GO:0051301 Cell division 187 7 4.2512 0.005
GO:0022402 Cell cycle process 334 9 4.22 0.003
GO:0045739 Positive regulation of DNA repair 5 2 3.5589 0.03
GO:0051726 Regulation of cell cycle 248 7 3.4893 0.026
GO:0000082 G1 S transition of mitotic cell cycle 30 3 3.2793 0.032
GO:0009132 Nucleoside diphosphate metabolic process 7 2 3.2397 0.036
GO:0051329 Interphase of mitotic cell cycle 76 4 3.1561 0.035
GO:0006259 DNA metabolic process 373 8 3.1266 0.031
GO:0006282 Regulation of DNA repair 8 2 3.1162 0.039
GO:0051325 Interphase 79 4 3.0926 0.036
GO:0006396 RNA processing 298 7 3.0138 0.038
GO:0009262 Deoxyribonucleotide metabolic process 9 2 3.0086 0.042
GO:0007059 Chromosome segregation 38 3 2.9748 0.04
This table contains the enriched GO categories of the down-regulated divergent genes. The first column includes the GO terms and description. 
The second column contains the total number of genes for that given category on the Agilent microarray. The third column shows the number of 
down-regulated divergent genes for that category. The fourth column lists the -log10 probability associated with that categories. The fifth column 
contains the false discovery rate.
Table 2: Top 15 enriched transcription factor binding sites
TF Name Biological Process Functional Category Reference
1) C/EBP Acute myeloid leukemia Tumor Progression [63]
2) HLF Acute lymphoblastic leukemia Tumor Progression [67]
3) PAX6 Eye development Development [90]
4) TAL1/SCL Lymphocytic leukemia Tumor Progression [91]
5) HOXA4 Chronic lymphocytic leukemia Tumor Progression [73]
6) CDP/CUTL1 Mediate cell cycle progression Cell Cycle [92]
7) AML/RUNX1 Acute myeloid leukemia Tumor Progression [93]
8) TBP Required for RNA Pol II General Transcription [94]
9) MEIS1 Acute myeloid leukemia Tumor Progression [79]
10) OCT-1/POU2F1 Regulates cyclin D1 w/STAT5 Cell Cycle [95]
11) RAR-RXR Acute promyelocytic leukemia Tumor Progression [81]
12) POU3F2 Neuronal development Development [96]
13) FOXO4/AFX Mixed lineage leukemia Tumor Progression [82]
14) SOX9 Chondrogenesis Development [97]
15) POU1F1 Pituitary hormone secretion Development [98]
This table contains the top 15 enriched transcription factors binding sites found in the promoters of divergent genes, with literature references that 
link these factors to general functional categories of tumor progression, cell cycle, and development. The first column includes the transcription 
factor name. The second column contains the biological processes with which these factors are associated. The third column lists the general 
functional categories of these factors. The fourth column points to the literature references for these factors.BMC Systems Biology 2009, 3:20 http://www.biomedcentral.com/1752-0509/3/20
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bers of which are required to specify particular stages of
hematopoietic development [72]. Further, HoxA4 pro-
moter hypermethylation has recently been linked to
mutational status in chronic lymphocytic leukemia [73].
AML/Runx1 is also linked to hematopoiesis and leukemic
tumor progression [74]. It is the DNA binding element of
the core binding factor (CBF) transcription complex and
is required for hematopoiesis as shown in knock-out
mouse studies [75]. Mutations of RUNX1 have been iden-
tified in familial platelet disorder (FPD) along with a con-
genital predisposition to the development of acute
myeloid leukemia (AML) [76]. MEIS1, another protein
with enriched TFBS, cooperates with both HOXB3 and
HOXA9 to induce the transcription factor AML [77,78] by
down-regulating its expression through promoter hyper-
methylation in a subset of AMLs [79]. The RAR-RXR het-
erodimer TFBS is also enriched in the promoter regions of
our divergent genes. Since the HL60 neutrophil differenti-
ation is induced through the actions of retinoid acid, it is
reasonable that we observed an enrichment of retinoid
acid receptor binding sites. Though it is well-established
that the chimeric fusion protein from RAR-PML transloca-
tion mutation, t(15;17), is frequently associated with
acute promyelocytic leukemia [80], methylation analysis
of the RAR   promoter further cements its involvement
[81]. Finally, FOXO4 has also been linked with acute
leukemias. A translocation mutation t(X;11)(q13;q23),
which fuses it with the gene MLL, was observed and
cloned [82]. In summary, the list of enriched TFBSs reca-
pitulates many important regulators of hematopoiesis,
which are intimately tied to leukemia pathology, illustrat-
ing the potential utility of such systems-level experimental
designs.
Conclusion
In this study, we perturbed the HL60 cells into the basins
of attraction of two distinct cell fate attractors using two
different ATRA dosage/duration treatments such that both
cell populations are poised at the same stage of differenti-
ation. By tracking the gene expression changes en route to
these cell fates, we found a subset of the differentially
expressed genes that exhibited a divergent gene expression
pattern, hypothesized to correspond to the observed mac-
roscopic cell type phenotype. Literature searches identi-
fied the possible functions of these divergent genes to be
involved in promoting neutrophil differentiation and
repressing cell cycle progression. Analyses of the promoter
sequences of the divergent genes further showed that they
are enriched with transcription factor binding sites known
to be linked to hematopoiesis, tumorigenesis, cell cycle,
and development, suggesting the utility of systems level
analysis for deriving valuable molecular level insights.
It is worth noting that our study suffers from a number of
inherent limitations. With our attractor-based experimen-
tal setup, we could not detect early onset genes that lead
to the "precommitment" state. Since gene expression pro-
files are only recorded after the two populations of the
cells have achieved similar percentages of CD11b expres-
sion, prior cellular events of interest that culminate in
their perspective promyelocyte and neutrophil attractors
would be missed. In addition, since our study is based on
a population of cells, inherent to all microarrays studies,
only measurements of the average cellular behavior are
possible. Indeed, it is known that the expression kinetics
on a single cell level can exhibit an all-or-none switch like
behavior, unlike the seemingly gradual change of expres-
sion when measured as a population average [39]. Fur-
ther, recent evidence now suggests that transcriptional
noise inherent to individual cells underlies clonal hetero-
geneity [83]. In light of this, an analysis on the gene
expression changes of individual cells flowing toward the
promyelocyte and neutrophil attractors would provide
valuable insights.
Our study also suggests a number of natural extensions.
For example, since transcription factor binding sites fre-
quently occur in clusters and exert their effects simultane-
ously, instead of looking for enrichment of individual
transcription factors, one can investigate enrichment of
multiple transcription factors. Another possible extension
is the incorporation of protein-protein interaction net-
works in order to identify potential co-activators of the
transcriptional complexes governing HL60 differentia-
tion. Further, one can search for common interaction
partners to multiple enriched transcription factors. Addi-
tionally, in our characterization of divergent genes, com-
parisons of gene expression were made on a daily basis. To
mitigate the effects of measurement noise and daily fluc-
tuations, it is possible to model the entire time course
gene expression profile for each gene by fitting a regres-
sion curve, promoting a possibly more robust identifica-
tion of divergent genes.
Our study also raises an important question – can the con-
cept of cell fate be sufficiently described by the use of one
or few markers? Traditionally, cell fate has been intimately
tied to the expression of cell surface receptors. However,
in our study, two populations of ATRA-stimulated HL60
cells can both exhibit characteristic cell fate markers, yet
be destined to have distinct cell fates, namely a promyelo-
cyte or a neutrophil. This suggests two populations of cells
may have the same "apparent" state as measured by cell
surface markers while differing in other state space dimen-
sions, ultimately leading them to disparate cell fates. Like-
wise, Chang et al. [39] also came to similar conclusions in
their observation that low-dose DMSO-treated CD11b-
cells are in a "primed" differentiated state as compared to
DMSO-untreated CD11b- cells.BMC Systems Biology 2009, 3:20 http://www.biomedcentral.com/1752-0509/3/20
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This study suggests that systems-level dynamics, such as
the partitioning of the state space into distinct basins of
attraction, have the potential to convey information
about the molecular-level control of biological processes.
Methods
Cells and chemicals
Early passaged HL60 cells were generously provided by
Dr. Steven Collins (Fred Hutchinson Cancer Research
Center). The cells were cultured in T/25 flasks with RPMI-
1640 media (Gibco) supplemented with 10% heat-inacti-
vated fetal calf serum (Sigma). Cells were grown in media
containing All-Trans Retinoic Acid (Sigma) to induce neu-
trophil differentiation [33]. ATRA was stored in -30°C
and dissolved in 95% ethanol to make stock solution.
Dosage and duration of ATRA treatments
A two-factor dosage and duration experiment was set up
with eight and ten levels, respectively. HL60 cells were
subjected to the following dosages ( M): 1, 0.5, 0.1, 0.05,
0.01, 0.005, 0.001, and 0.0005 in conjunction with the
following durations (Days of Treatment): 4, 5, 6, 7, 8, 9,
10, 11, 12, and 13. For example, one of the eighty treat-
ment combinations is 1  M/4 Days, in which, we treated
the HL60 cells with 1  M of ATRA for 4 Days and measured
the CD11b expression of these treated cells by flow
cytometry. Each of the 80 dosage/duration combinations
and CD11b measurements were performed in triplicate.
Flow cytometry to detect surface CD11b expression
Surface CD11b is an early marker of neutrophil differenti-
ation in HL60. Cells (106) were harvested, washed twice
with PBS buffer, and incubated on ice for an hour with PE-
conjugated CD11b antibody or its isotype control (Mouse
IgG1 ) from BD Pharmingen. Cells were then washed two
more times with PBS buffer and fluorescence was meas-
ured by FACSCalibur using CellQuest software (BD Bio-
sciences). The CD11b expression levels were compared to
the isotype control to correct for any non-specific binding.
Untreated HL60 cells stained with the isotype control
were used as background for undifferentiated cells.
Dosage and duration contour plot construction
One million cells were collected for each experiment. Per-
centages of CD11b+ expression were calculated by com-
paring ATRA treated HL60 samples to untreated samples.
Triplicate values of the percentage of differentiation were
averaged and the result was displayed as a contour plot
(Figure 1). In constructing the dosage/duration contour
plot, one round of linear interpolation was performed to
obtain a finer sampling of the dosage/duration grid.
Wright-Giemsa stain to observe nuclear morphology
Treated and untreated cells (105) were harvested, washed
once with PBS buffer, spun down on microscope slides
using Cytospin 2 (Shandon Inc.) and air-dried. Slides
were then flooded with 2 mL Modified Wright-Giemsa
stain (Sigma-Aldridge) and soaked for 1 minute. 2 mL
deionized water was added, the slides were soaked for 3
minutes, rinsed with deionized water, and air dried.
Microarray experiment and analysis to measure changes in 
mRNA levels
Two treatment combinations that yielded similar levels of
CD11b expression were identified from the dosage and
duration contour plot: 1) high dosage/short duration (1
M ATRA/5 Days) and 2) low dosage/long duration (0.05
M ATRA/7 Days). HL60 cells were cultured under these
two conditions and fifteen million CD11b positive cells
were collected from each condition using the Cytopeia
inFlux V-Gs high-speed sorter. Sorted CD11b positive
cells were then re-cultured in fresh ATRA-free RPMI
media. After six hours of allowing these cells to recover
from the sorting process, one million cells were collected.
For the next five days, one million cells were collected
every twenty-four hours, culminating in a total of 5 time
points – Day 0 (6 hours post-sorting) to Day 4 (102 hours
post sorting). For each time point, total RNA from cell
samples were isolated with Trizol and quantified using
Thermo Scientific NanoDrop 1000. RNA quantity for
three technical replicates was collected for each time
point, except day0, day1, and day4 of the 1  M treatment,
where unfortunately the RNA quantity was only sufficient
for two replicates, resulting in a total of 27 microarray
experiments on Agilent human whole genome oligo
arrays with 44 k 60-mer probes. ATRA-treated samples
from each time point were labeled with the Cy5 dye, while
untreated HL60 cells were labeled with the Cy3 dye for
comparison. Each hybridized array was scanned with the
Agilent dual laser-based scanner. Feature Extraction soft-
ware version 8.0 (Agilent Technologies) was used to out-
put the relative fluorescence intensity between the treated
and untreated samples.
After the microarray experiments, the slides were scanned
and the raw spot intensity (gProcessedSignal and rProc-
essedSignal from the feature extraction software) were
used for subsequent data analysis in Matlab (The Math-
works, Inc). Of the 43931 spots on the Agilent array, spots
that were designated for quality control, spots that were
saturated, and spots that had signals too low to be
detected were filtered out, resulting in 41509 spots
remaining. The log intensity values were normalized
using quantile normalization [84]. Replicate array inten-
sity values were averaged to obtain the mean fluorescence
intensity. Differentially expressed genes were picked using
SAM [85] (Two class Paired). After this filtering step,
14949 differentially expressed genes remained. We com-
pared the expression of 1  M ATRA/5 Days treatment with
0.05  M ATRA/7 Days treatment to identify genes thatBMC Systems Biology 2009, 3:20 http://www.biomedcentral.com/1752-0509/3/20
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showed a steady daily increase of divergence in expression
of 5% or larger, and designated these as divergent genes.
Of these genes, those with elevated (respectively, sup-
pressed) expression under both 1  M ATRA/5 Days treat-
ment and 0.05  M ATRA/7 Days treatment relative to the
untreated condition during the first three time points were
deemed to be up-regulated (respectively, down-regu-
lated). Comparisons of expressions were done on a daily
basis, yielding a total of 176 divergent probes, 48 up-reg-
ulated and 128 down-regulated. A complete list of diver-
gent gene probes is available in the supplementary
section. Gene probes are sorted based on log2 fold diver-
gence of Day 4 expression between 1  M ATRA/5 Days
treatment and 0.05  M ATRA/7 Days treatment. The 176
divergent spots identified corresponded to 154 unique
genes, 48 up-regulated genes and 106 down-regulated
genes (some genes have multiple probes on the array).
Functional enrichment of divergent genes by Gene 
Ontology (GO)
Up-regulated divergent genes and down-regulated diver-
gent genes were submitted separately to GoMiner [62] for
an analysis of enriched biological processes at the p-value
level of 0.05 and FDR of 0.05.
Searching for enriched transcription factor binding sites
Upstream 2 kb promoter regions of the divergent genes
were downloaded from EMBL (NCBI36) using the
BioMart interface [86]. Prepackaged upstream 2 kb
regions of all RefSeq genes were also downloaded using
the UCSC genome browser (hg18) [87]. After filtering out
duplicated sequences and sequences containing ambigu-
ous nucleotide bases, 18827 sequences remained. 429
human TRANSFAC (Professional 9.4) matrices [88] were
used to calculate the log likelihood ratio scores of tran-
scription factor binding for the divergent genes as well as
the RefSeq genes, as
where L is the log likelihood ratio score, Ms is the TRANS-
FAC matrix model, Mb is the zeroth order Markov back-
ground model with frequencies of A:0.2583 C:0.2457
G:0.2425 T:0.2535, which were calculated by counting
the occurrences of the nucleotides in all promoter
sequences. si is the ith nucleotide of the motif site under
consideration, and n is the length of the motif site.
Since binding sites tend to occur in clusters in higher
eukaryotes [89], attention was paid to find stretches of the
DNA sequences (100 bp) with large numbers of putative
binding sites. Hence, log likelihood ratio scores from all
429 TRANSFAC matrices were summed at each nucleotide
position for all RefSeq promoter sequences. The top 1% of
these 100 bp highest scoring regions were picked as cut-
off values to represent regions with clusters of putative
binding sites. This cut-off value was then used to search
for clusters of putative binding sites in the divergent
genes, resulting in 262 of these clusters of binding sites
being identified for the divergent genes. Expected num-
bers of binding sites were calculated by counting the total
number of binding sites within the high-scoring regions
divided by the total number of high-scoring regions for
each transcription factor. This calculation was repeated for
each TRANSFAC matrix. Enriched transcription factor
binding sites were then ranked by the differences between
the expected values for the divergent gene set and the set
of all RefSeq promoters (Table 2).
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